Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Procaps GroupS. A. develops, produces, and markets pharmaceutical solutions worldwide.
The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.
It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals.
Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies.
The company was founded in 1977 and is based in Luxembourg, Luxembourg.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 28, 24 | 0.00 Decreased by -100.00% | - |
| Feb 28, 24 | 0.00 Decreased by -100.00% | 0.09 Decreased by -100.00% |
| Dec 26, 23 | 0.08 Decreased by -63.64% | 0.05 Increased by +60.00% |
| Sep 5, 23 | 0.27 Increased by +485.71% | 0.06 Increased by +350.00% |
| May 12, 23 | 0.10 Decreased by -64.29% | 0.01 Increased by +900.00% |
| Dec 31, 22 | 0.10 Decreased by -64.29% | 0.01 Increased by +900.00% |
| Nov 14, 22 | 0.22 Increased by +266.67% | 0.13 Increased by +69.23% |
| Aug 30, 22 | -0.07 Increased by +75.00% | 0.01 Decreased by -800.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 118.41 M Increased by +7.25% | 8.19 M Decreased by -63.71% | Increased by +6.92% Decreased by -66.17% |
| Jun 30, 23 | 118.41 M Increased by +5.33% | 8.19 M Increased by +218.43% | Increased by +6.92% Increased by +212.44% |
| Mar 31, 23 | 101.47 M Decreased by -19.81% | 10.43 M Increased by +122.54% | Increased by +10.28% Increased by +128.11% |
| Dec 31, 22 | 101.47 M Decreased by -19.81% | 10.43 M Increased by +122.54% | Increased by +10.28% Increased by +128.11% |
| Sep 30, 22 | 110.40 M Increased by +3.35% | 22.58 M Increased by +161.69% | Increased by +20.45% Increased by +159.69% |
| Jun 30, 22 | 112.42 M Increased by +13.63% | -6.92 M Decreased by -966.10% | Decreased by -6.15% Decreased by -838.22% |
| Mar 31, 22 | 126.54 M Increased by +63.39% | -46.29 M Decreased by -167.30% | Decreased by -36.58% Decreased by -63.59% |
| Dec 31, 21 | 126.54 M Increased by +7.10% | -46.29 M Decreased by -590.13% | Decreased by -36.58% Decreased by -557.64% |